Hospital Professor Doutor Fernando Fonseca, E.P.E.

Amadora-Lisbon 2610-276

1 studies enrolling now · 2 studies all time

What they study most

First Line Non-Small Cell Lung Cancer, HER2-positive Breast Cancer

Studies at this site

• RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive — Recruiting now
• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed